Publicación:
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy

Página de artículo simple
dc.contributor.author Tume, L es_PE
dc.contributor.author Paco, K es_PE
dc.contributor.author Ubidia-Incio, R es_PE
dc.contributor.author Moya, J es_PE
dc.date.accessioned 2024-05-30T23:13:38Z
dc.date.available 2024-05-30T23:13:38Z
dc.date.issued 2016
dc.description.abstract Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome. © 2016 Sociedad Mexicana de Oncología. en
dc.description.sponsorship Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - Concytec
dc.identifier.doi https://doi.org/10.1016/j.gamo.2016.01.003
dc.identifier.isi 457388700019
dc.identifier.uri https://hdl.handle.net/20.500.12390/959
dc.language.iso eng
dc.publisher Permanyer Publications en
dc.relation.ispartof Gaceta Mexicana de Oncología
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject Breast cancer en
dc.subject CD133 en
dc.subject Immunotherapy en
dc.title CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy
dc.type info:eu-repo/semantics/article
dspace.entity.type Publication
oairecerif.author.affiliation #PLACEHOLDER_PARENT_METADATA_VALUE#
Archivos
Colecciones
1.1 Eventos institucionales
 7.1 Incentivos para publicaciones indizadas